---
title: 'Analysis of measurable residual disease by IG/TR gene rearrangements: quality
  assurance and updated EuroMRD guidelines'
date: '2024-05-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38744919/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240515180808&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Minimal/measurable residual disease (MRD) diagnostics using real-time
  quantitative PCR analysis of rearranged immunoglobulin and T-cell receptor gene
  rearrangements are nowadays implemented in most treatment protocols for patients
  with acute lymphoblastic leukemia (ALL). Within the EuroMRD Consortium, we aim to
  provide comparable, high-quality MRD diagnostics, allowing appropriate risk-group
  classification for patients and inter-protocol comparisons. To this end, we set
  up a quality ...
disable_comments: true
---
Minimal/measurable residual disease (MRD) diagnostics using real-time quantitative PCR analysis of rearranged immunoglobulin and T-cell receptor gene rearrangements are nowadays implemented in most treatment protocols for patients with acute lymphoblastic leukemia (ALL). Within the EuroMRD Consortium, we aim to provide comparable, high-quality MRD diagnostics, allowing appropriate risk-group classification for patients and inter-protocol comparisons. To this end, we set up a quality ...